Transcriptomics

Dataset Information

0

Self-associated molecular patterns mediate cancer immune evasion by engagement of Siglec receptors


ABSTRACT: Cancer immunotherapy targeting inhibitory receptors on T cells has changed the landscape of oncological practice, but most patients do not respond to current approaches. Thus, new targets on T cells for cancer immunotherapy are needed. CD33-related Siglecs are pattern recognition immune receptors binding to a broad range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) to dampen unwanted immune responses against self. Naïve T cells in humans have very low levels of inhibitory Siglec expression. Here, we show Siglec-9 in non-small cell lung cancer (NSCLC) are significantly upregulated on tumor-infiltrating T cells. These findings were confirmed in other tumor types including colorectal cancer, and ovarian cancer. Characterization of Siglec-9 expressing T cells showed a co-expression of inhibitory receptors including PD-1 and a distinct phenotype with increased cytokine production upon restimulation, compared to Siglec negative T cells. Functional analysis by reduction of sialoglycan-SAMPs on tumor cells in vitro and in vivo demonstrated an increased tumor cell killing and an inhibition of tumor growth. Overexpression of inhibitory Siglecs on T cells enhanced tumor growth in mice and exchange of inhibitory Siglecs on mouse T cells with an activating Siglec enhanced anti-cancer immunity. Increased T cell expression of Siglec-9 in NSCLC patients also correlated with survival, and analysis of Siglec-9 polymorphisms showed an association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as potential new target to improve T cell activation and cancer immunotherapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE115305 | GEO | 2018/12/26

REPOSITORIES: GEO

Similar Datasets

2023-05-22 | GSE229054 | GEO
2022-03-07 | PXD032064 | JPOST Repository
2024-03-27 | GSE262087 | GEO
2018-02-09 | PXD008406 | Pride
2024-03-27 | GSE262085 | GEO
2020-05-26 | E-MTAB-9112 | biostudies-arrayexpress
2022-03-23 | GSE190700 | GEO
2024-03-27 | GSE262086 | GEO
2022-11-24 | GSE208133 | GEO
2019-12-29 | GSE142694 | GEO